Home > Research Programs > Thoracic Tumors Group
Thoracic Tumors Group
Strategic Goals
- Optimization of multidisciplinary treatment in patients with stage I-III cancer
- Early integration of genetic determinations to personalize treatments
- Participation in the development of new drugs
- Active intervention in the fight against smoking
Current objectives
- Implement the determination ALK translocation
- Study the efficacy of PI3K/mTOR inhibitors in patients with lung cancer resistant to EGFRTKIs
- Study the efficacy of PARP inhibitors in lung cancer
- Analyze the epidemiologic/clinical characteristics of women diagnosed with lung cancer
- Play an active role in organizing a European consensus meeting on lung cancer
Team
Medical Oncologists
- Susana Cedrés MD
- Pablo Martínez MD
Graduate Students
- Marina Longo
- Mireia Cazorla
- Eva Checa
Publications
- Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009 Nov; 66(2): 257-61
- Muñoz E, Cedrés S, Felip E. Rare tumours of the chest. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 400-1
- Felip E, Garrido P, Trigo JM, López-Brea M, Paz-Ares L, Provencio M, Isla D. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2009 May; 11(5): 284-9
- Ingelido AM, Abballe A, di Domenico A, Fochi I, Iacovella N, Saragosa A, Spagnesi M, Valentini S, De Felip E. Levels and profiles of polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and polychlorinated biphenyls in feedstuffs and milk from farms in the vicinity of incineration plants in Tuscany, Italy. Arch. Environ. Contam. Toxicol. 2009 Aug; 57(2): 397-404
- Manchon Walsh P, Manchon P, Borras JM, Ferro T, Espinàs JA. Lung Cancer OncoGuia. Clin Transl Oncol 2009 Dec; 11(12): 805-24
